Despite certain studies carried out at the beginning of 2021, which showed that 50% of the population of large Indian cities had immunity, it seems that these results were not representative of the population as a whole. The rapid and sudden increase in the number of cases, from March 2021 onwards, appears to have been due to several factors. Firstly, there was the appearance of an Indian variant that seemed to be more infectious. It has 2 mutations in the spike protein, L452R and E484Q, that give it higher infectivity and, potentially, the ability to evade immune responses. In addition, the rate of vaccination in the country is low. And finally, public health measures that had been put in place in 2020, had been largely relaxed before the beginning of this wave of the epidemic.
Reliable epidemiological data is difficult to obtain in India: a large percentage of infected people are asymptomatic, and the majority of the population does not have access to testing. In addition, cause of death is noted on only 20% of death certificates. Several studies have analysed data from the most densely populated cities in the country. The rate of mortality has been calculated as 41 deaths per 100 000 inhabitants, substantially less than the rate of 91 deaths observed in the US.